ADMA Biologics Under Investigation for Potential Federal Securities Law Violations

Lowey Dannenberg P.C., a prominent complex litigation law firm, has announced an investigation into ADMA Biologics (NASDAQ: ADMA) concerning potential violations of federal securities laws. The investigation, disclosed on April 10, 2026, by the firm, focuses on whether ADMA Biologics and certain of its officers and directors engaged in unlawful business practices or made misleading statements to investors.

The investigation by Lowey Dannenberg P.C. is a preliminary step to determine if there are grounds for a class action lawsuit on behalf of affected shareholders. Such investigations typically arise when a company's stock price experiences significant declines following disclosures that suggest prior misrepresentations or omissions of material information. The firm is inviting investors who have suffered losses due to their investments in ADMA Biologics to contact them to discuss their legal options.

While the Financial Post report primarily details the initiation of this investigation by Lowey Dannenberg P.C., it does not provide specific details regarding the nature of the alleged violations or the period during which these violations may have occurred. The announcement serves as a notice to investors about the ongoing legal scrutiny faced by ADMA Biologics.